Laekna Therapeutics Files for IPO on Hong Kong Stock Exchange, Aims to Expand Cancer and Hepatic Fibrosis Therapies
China’s Laekna Therapeutics Shanghai Co., Ltd has filed for an initial public offering (IPO) with...
Cancer
Juventas Cell Therapy’s CNCT19 Receives FDA IND Approval for r/r B-ALL Treatment
China-based Juventas Cell Therapy Ltd’s chimeric antigen receptor (CAR) T-cell therapy, CNCT19 (Inaticabtagene Autoleucel), has...
Bio-Thera Solutions Initiates First Patient Dosing in Phase I Study of BAT8007
China-based Bio-Thera Solutions, Ltd. (SHA: 688177) has announced the first patient dosing in a multi-center,...
Antengene to Begin Phase I Clinical Study of ATG-022 for Advanced Solid Tumors
China-based Antengene Corporation Ltd (HKG: 6996) is poised to commence a Phase I clinical study...
Akeso Biopharma Enrolls First Subject in Phase III Study of Cadonilimab for Gastric Cancer
China-based Akeso Biopharma (HKG: 9926) has announced the enrollment of the first subject in a...
CSPC Pharmaceutical’s PD-1 Monoclonal Antibody Enlangsubai Completes NMPA Market Approval Filing
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the completion of a market approval...
Chipscreen’s Epidaza Receives TFDA Approval for Breast Cancer Treatment in Taiwan
Shenzhen Chipscreen Pharmaceutical Co., Ltd’s partner, GNT Biotech & Medicals Corporation, has announced that it...
XtalPi and Chia Tai Tianqing Achieve Phase II Milestone in Cancer Drug Development
Sino-US artificial intelligence (AI) firm XtalPi Inc. has partnered with China’s Chia Tai Tianqing to...
Haihe Pharmaceutical Initiates Global Phase I Clinical Study for BET-BD2 Inhibitor HH3806
Shanghai Haihe Pharmaceutical Co., Ltd has announced the first patient dosing of a global multi-center...
Zenshine Pharmaceuticals Raises RMB 100 Million in Series B Financing for Drug Development
China-based small molecule drug developer Nanjing Zenshine Pharmaceuticals Co., Ltd reportedly raised over RMB 100...
CStone’s Ayvakit Shows Significant Improvements in ISM at AAAAI Meeting
China-based CStone Pharmaceuticals (HKG: 2616) announced that its US partner, Blueprint Medicines, published detailed data...
Bio-Thera Solutions Initiates Phase I Study for Trop2-Targeting ADC BAT8008
China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced the first patient dosing in a multi-center,...
Astellas and Seagen File for NMPA Approval of Enfortumab Vedotin for Urothelial Carcinoma
Japan-based Astellas Pharma Inc. (TYO: 4503) and US biotech Seagen Inc. (Nasdaq: SGEN) have announced...
InnoCare Pharma Initiates Clinical Study for BCL2 Inhibitor ICP-248 in China
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a...
Bio-Thera Solutions Initiates Phase I Study for Trop2-Targeting ADC BAT8008
China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced the first patient dosing in a multi-center,...
Astellas and Seagen File for NMPA Approval of Enfortumab Vedotin for Urothelial Carcinoma
Japan-based Astellas Pharma Inc. (TYO: 4503) and US biotech Seagen Inc. (Nasdaq: SGEN) have announced...
InnoCare Pharma Initiates Clinical Study for BCL2 Inhibitor ICP-248 in China
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a...
Haihe Pharma’s Glumetinib Gains Conditional NMPA Approval for NSCLC
Shanghai Haihe Pharmaceutical Co., Ltd’s Category 1 product, glumetinib, has received conditional market approval from...
JW Therapeutics Launches Carteyva Clinical Study for High-Risk Lymphoma
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...
Haihe Pharma’s Glumetinib Receives Conditional Approval for NSCLC Treatment
Shanghai Haihe Pharmaceutical Co., Ltd’s Category 1 product, glumetinib, has obtained conditional market approval from...